AP2013007153A0 - Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators - Google Patents

Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators

Info

Publication number
AP2013007153A0
AP2013007153A0 AP2013007153A AP2013007153A AP2013007153A0 AP 2013007153 A0 AP2013007153 A0 AP 2013007153A0 AP 2013007153 A AP2013007153 A AP 2013007153A AP 2013007153 A AP2013007153 A AP 2013007153A AP 2013007153 A0 AP2013007153 A0 AP 2013007153A0
Authority
AP
ARIPO
Prior art keywords
benzo
receptor modulators
sensing receptor
calcium sensing
oxazin
Prior art date
Application number
AP2013007153A
Other languages
English (en)
Inventor
Manojkumar Ramprasad Shukla
Sarde Gangaram Ankush
Pachpute Dilip Vipul
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of AP2013007153A0 publication Critical patent/AP2013007153A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2013007153A 2011-03-18 2012-03-16 Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators AP2013007153A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN367KO2011 2011-03-18
PCT/IB2012/051268 WO2012127388A1 (en) 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Publications (1)

Publication Number Publication Date
AP2013007153A0 true AP2013007153A0 (en) 2013-09-30

Family

ID=54192843

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013007153A AP2013007153A0 (en) 2011-03-18 2012-03-16 Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators

Country Status (16)

Country Link
US (1) US9464063B2 (OSRAM)
EP (1) EP2686306B1 (OSRAM)
JP (1) JP6033835B2 (OSRAM)
KR (1) KR20140051846A (OSRAM)
CN (1) CN103459377B (OSRAM)
AP (1) AP2013007153A0 (OSRAM)
AU (1) AU2012232706B2 (OSRAM)
BR (1) BR112013023914A2 (OSRAM)
CA (1) CA2829466A1 (OSRAM)
EA (1) EA024893B9 (OSRAM)
IL (1) IL228461A0 (OSRAM)
MX (1) MX2013010670A (OSRAM)
PH (1) PH12013501899A1 (OSRAM)
SG (1) SG193331A1 (OSRAM)
WO (2) WO2012127385A1 (OSRAM)
ZA (1) ZA201306837B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102041154B1 (ko) 2012-02-24 2019-11-07 루핀 리미티드 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
HK1211916A1 (en) * 2012-08-27 2016-06-03 Lupin Atlantis Holdings Sa Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
US9493396B2 (en) 2013-08-28 2016-11-15 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
EP3060563B1 (en) 2013-10-25 2018-05-02 Novartis AG Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
PL3200786T3 (pl) 2014-10-03 2020-03-31 Novartis Ag Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
CN104464530B (zh) * 2014-11-18 2017-08-25 深圳市华星光电技术有限公司 曲面型显示装置
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
MX394242B (es) 2017-01-11 2025-03-24 Rodin Therapeutics Inc Inhibidores biciclicos de histona desacetilasa
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.
BR112022012663A2 (pt) 2019-12-27 2022-09-06 Lupin Ltd Composição farmacêutica de moduladores de casr e métodos e usos da mesma
AU2021207775B2 (en) * 2020-01-17 2025-12-11 Lupin Limited Methods, processes and intermediates for preparing chroman compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109880A (zh) 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
FR2809396B1 (fr) * 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
CA2527203C (en) 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
CA2608194A1 (en) * 2005-05-09 2006-11-16 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
PL1882684T3 (pl) * 2005-05-19 2015-08-31 Astellas Pharma Inc Pochodna pirolidyny albo jej sól
CN101547922B (zh) 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
AU2007318092B2 (en) * 2006-10-26 2013-01-10 Amgen Inc. Calcium receptor modulating agents
EP2085383A4 (en) 2006-11-16 2010-09-22 Astellas Pharma Inc Piperidin derivatives or salts thereof
BRPI0819799A2 (pt) 2007-11-23 2015-05-26 Leo Pharma As Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
WO2010038895A1 (ja) 2008-10-03 2010-04-08 味の素株式会社 ＣａＳＲアゴニスト
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010090069A1 (ja) * 2009-02-05 2010-08-12 ヤンマー株式会社 Ｅｇｒ装置及びこれを備えたエンジン装置
CA2762137A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体

Also Published As

Publication number Publication date
US9464063B2 (en) 2016-10-11
BR112013023914A2 (pt) 2016-12-13
WO2012127388A1 (en) 2012-09-27
AU2012232706B2 (en) 2016-12-15
SG193331A1 (en) 2013-10-30
CN103459377A (zh) 2013-12-18
IL228461A0 (en) 2013-12-31
EA024893B9 (ru) 2017-01-30
MX2013010670A (es) 2013-12-06
CN103459377B (zh) 2016-09-07
ZA201306837B (en) 2015-05-27
US20140018358A1 (en) 2014-01-16
NZ616676A (en) 2015-09-25
CA2829466A1 (en) 2012-09-27
JP2014510097A (ja) 2014-04-24
WO2012127385A1 (en) 2012-09-27
KR20140051846A (ko) 2014-05-02
PH12013501899A1 (en) 2013-11-25
EA201370205A1 (ru) 2014-01-30
EP2686306A1 (en) 2014-01-22
EA024893B1 (ru) 2016-10-31
EP2686306B1 (en) 2017-01-04
AU2012232706A1 (en) 2013-09-26
JP6033835B2 (ja) 2016-11-30

Similar Documents

Publication Publication Date Title
IL228461A0 (en) Derivatives of benzo[1,4]oxazines as modulators of calcium-sensing receptors
ZA201306576B (en) Substituted morpholines as modulators for the calcium sensing receptor
LT3093291T (lt) Dipakeistieji oktahidropirolo [3,4-c]pirolai, kaip oreksino receptoriaus moduliatoriai
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
ZA201306817B (en) Spirocyclic isoxazoline derivatives as antiparasitic agents
ZA201206193B (en) Dihydrofuran derivatives as insecticidal compounds
EP2741721A4 (en) MOISTURE SENSORS
SI2598503T1 (sl) Derivati cis-tetrahidro-spiro(cikloheksan-1,1'-pirido(3,4-b)indol)-4-amina
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
IL232917A0 (en) History of 5-(3-aminophenyl)-5-alkyl-6,5-dihydro-2h[4,1]oxazin-3-amine
BR112013023056A2 (pt) derivados de oxaespiro [2,5] octano e análogos
ZA201405990B (en) Substituted chroman compounds as calcium sensing receptor modulators
ZA201404074B (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
GB201100991D0 (en) Fibre-optic sensor
IL220707A0 (en) 2,5,7-substituted oxazolopyrimidine derivatives
IL235681A0 (en) 5- amino [1, 4] thiazines as 1 bace inhibitors
ZA201302112B (en) 1,4-oxazepane derivatives
IL236473B (en) 1, 5-dihydro-2-pyrrole-one derivatives as cholecystokinin receptor ligands
ZA201501053B (en) Arylalkylamine compounds as calcium sensing receptor modulators
PL2814825T3 (pl) Dihydrofuranowe pochodne azetydyny jako środki przeciwpasożytnicze
BR112013015223A2 (pt) derivados de 1,2-bis-sulfonamida como moduladores de receptores de quimiocinas
IL228270A0 (en) History of 1-h- pyrrolidine -4,2-dione spirocyclics converted in cis-alkoxy
GB201114825D0 (en) Fibre-optic sensor
PL119879U1 (pl) Zespól libelki poziomej zwlaszcza poziomnicy